Updated time: 2024-08-09 08:29:36
28A-1070928
2020-07-30
TW I842739、JP 7510182、PCT patents pending
FRIL, a plant lectin isolated from the hyacinth bean, has potent antiviral activity against diverse influenza virus strains. FRIL is effective in vivo against H1N1. FRIL’s antiviral activity is mediated by binding to complex type N-glycans on viral glycoproteins, interfering with viral entry. Lablab purpureus FRIL may also have broad specificity for other enveloped viruses with glycosylations. These findings indicate that Lablab purpureus FRIL can serve as a neutralization agent for viruses.
- FRIL can effectively neutralize various influenza A and B viruses.
- FRIL preferentially binds to complex type N-glycans on viral glycoproteins.
- Lablab beans can be used for food, so FRIL is safe for human.
- Low cost.
- Coat FRIL on masks or be included in aerosol mists in a closed space.
- FRIL can be used in an inhaler.

Fig1. FRIL can interfere with viral invasion.

Fig2. (A) Treatment schedule of H1N1 virus challenge and FRIL administration. (B) Survival was tracked for 21 days following influenza virus challenge.
Che MA、Jia-Tsrong Jan、Yo-Min Liu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

ANTIVIRAL LECTIN AND USES THEREOF